Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants
A Pilot Study
Bibliographic Data
| ID | 15519376 |
|---|---|
| Authors | Panagiotis Ferentinos (0000-0001-8531-5623, National and Kapodistrian University of Athens), Eirini Maratou (0000-0002-9982-7942, National and Kapodistrian University of Athens), Anastasia Antoniou (0000-0001-9557-8793, National and Kapodistrian University of Athens), Alessandro Serretti (0000-0003-4363-3759, University of Bologna), Nikolaos Smyrnis (0000-0002-1461-6151, National and Kapodistrian University of Athens), Paraskevi Moutsatsou (0000-0001-9549-2295, National and Kapodistrian University of Athens, corresponding author) |
| Year | 2021 |
| Volume | 12 |
| Pages | 801738-801738 |
| Publication date | 2021-12-24 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2021.801738 |
| PMID | 35002816 |
| OpenAlex | W4200084941 |
| Language | EN |
| References cited | 64 |
Interleukin-1 beta (IL1β) is primarily produced by monocytes in the periphery and the brain. Yet, IL1β protein levels have to date been investigated in major depressive disorder (MDD) and antidepressant response using either plasma or serum assays although with contradictory results, while mononuclear cell assays are lacking despite their extensive use in other contexts. In this pilot study, we comparatively assessed IL1β in mononuclear lysates and plasma in depressed MDD patients over treatment and healthy controls (HC). We recruited 31 consecutive adult MDD inpatients and 25 HC matched on age, sex, and BMI. Twenty-six patients completed an 8-week follow-up under treatment. IL1β was measured in both lysates and plasma in patients at baseline (T0) and at study end (T1) as well as in HC. We calculated ΔIL1β(%) for both lysates and plasma as IL1β percent changes from T0 to T1. Seventeen patients (65.4% of completers) were responders at T1 and had lower baseline BMI than non-responders ( p = 0.029). Baseline IL1β from either plasma or lysates could not efficiently discriminate between depressed patients and HC, or between responders and non-responders. However, the two response groups displayed contrasting IL1β trajectories in lysates but not in plasma assays (response group by time interactions, p = 0.005 and 0.96, respectively). ΔIL1β(%) in lysates predicted response ( p = 0.025, AUC = 0.81; accuracy = 84.6%) outperforming ΔIL1β(%) in plasma ( p = 0.77, AUC=0.52) and was robust to adjusting for BMI. In conclusion, ΔIL1β(%) in mononuclear lysates may be a longitudinal biomarker of antidepressant response, potentially helpful in avoiding untimely switching of antidepressants, thereby warranting further investigation
Biology · Biomarker · Cytokine · In vitro · Interleukin · Interleukin 2 · Peripheral · Peripheral blood · Peripheral blood mononuclear cell · Medicine · Mental Health Research Topics · Stress Responses and Cortisol · Tryptophan and brain disorders · Immunology · Internal Medicine · Pharmacology
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D
The role of inflammation in depression
A New Depression Scale Designed to be Sensitive to Change
Burden of Depressive Disorders by Country, Sex, Age, and Year
Peripheral cytokine and chemokine alterations in depression
| Citation velocity | historical |
|---|---|
| Highly cited | No |